NielsenIQ (NIQ) Unleashes the Power of a Connected User Experience With Consumer Panel and Retail Measurement Data Integrated on the NIQ Discover Platform
10.7.2024 16:00:00 EEST | Business Wire | Press release
NielsenIQ (NIQ) today announced the launch of an integrated user experience for its Consumer Panel clients globally. This brings the Full View of Retail measurement and Consumer Panel data to life on a single platform, NIQ Discover. With a focus on elevating the client experience, the Discover platform leverages a new cloud-based architecture and aggregation engine providing faster data accessibility and user flexibility.
NIQ's Discover platform for Consumer Panel is set to transform the consumer insights landscape. With its advanced analytical models and always-on capabilities, NIQ is leading the way in delivering actionable insights. Clients can now enjoy a modern and intuitive interface that enhances their interaction with the platform, opening endless possibilities to analyze consumer behaviors to drive growth. “NIQ has made significant investments in our global consumer panel capabilities in the past year, enhancing performance, quality and usability of data driven insights. The launch of this modern, cloud-based platform is one of several enhancements we are making to our Consumer Panel offerings globally. Clients will now get access to panel data together with retail measurement, delivering a connected user experience,” said Kris Ewing, President, Global Consumer Panel Services, NIQ.
Key benefits of NIQ Discover platform for Consumer Panel include:
- Elevated user experience: On-demand insights unlocked through an intuitive and powerful visualization experience, side-by-side with retail measurement data, enabling seamless, guided flows that cross complementary data sets.
- Flexibility: Clients can build their own analyses and get results on-the-fly, opening a world of possibilities across different dimensions of people groups, facts, products, retailers, geographies, periods and demographics.
- On-demand Data: Access to advanced analytical models elevates the data analysis experience seamlessly within seconds. Clients can access key performance indicators like penetration in addition to more sophisticated analytical models like Super Shifting, Key Item Ranking, Assortment Optimizer and Portfolio Trial and Repeat
- Gen AI-driven insights through NIQ Ask Arthur: Consumer panel on NIQ Discover enables users to leverage NIQ Ask Arthur, a groundbreaking Gen AI-driven tool, to aid in global search, streamline data analysis and facilitate informed decision-making.
NIQ’s Consumer Panel Services (CPS) provides the most complete and clear view of today’s consumers across 23 markets. Some of the enhancements NIQ is making to its Consumer Panel include:
- Expansion of panel sample sizes globally, with broader coverage and representation across North America, West Europe, and Pacific.
- The best data: Delivering the Full View of consumer behavior across retail channels and brands with panel quality and coverage the industry trusts.
- Expanded analytical capacity through industry-leading consumer experts who bring powerful insights to life, connecting NIQ’s Retail Measurement data, Consumer Panel and other NIQ offerings to drive growth for CPG and retailer clients.
NIQ Discover for CPS provides an unparalleled user experience, delivering the best quality, the widest coverage, and most sophisticated analytics all in a single platform. It redefines the way clients can harness the analytical power of NIQ data and elevate insights to unprecedented heights.
About NIQ
NielsenIQ (NIQ) is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in more than 95 countries covering 97% of GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710255063/en/
Contacts
sweta.patra@nielseniq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom